Comparitive open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane 7 and ICRF-187) in patients with advanced breast cancer; treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)

H. Rosing; W.W. ten Bokkel Huinink; A. Bult; J.H. Beijnen

Comparitive open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane 7 and ICRF-187) in patients with advanced breast cancer; treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)

H. Rosing
, W.W. ten Bokkel Huinink
, A. Bult
, J.H. Beijnen

extern

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	69-77
Number of pages	8
Journal	European Journal of Drug Metabolism and Pharmacokinetics
Volume	24
Publication status	Published - 1999

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

Rosing, H., ten Bokkel Huinink, W. W., Bult, A., & Beijnen, J. H. (1999). Comparitive open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane 7 and ICRF-187) in patients with advanced breast cancer; treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). European Journal of Drug Metabolism and Pharmacokinetics, 24, 69-77.

Rosing, H. ; ten Bokkel Huinink, W.W. ; Bult, A. et al. / Comparitive open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane 7 and ICRF-187) in patients with advanced breast cancer; treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). In: European Journal of Drug Metabolism and Pharmacokinetics. 1999 ; Vol. 24. pp. 69-77.

@article{716414d8c56c44a0ae59bf1a17c878d5,

title = "Comparitive open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane 7 and ICRF-187) in patients with advanced breast cancer; treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)",

author = "H. Rosing and \{ten Bokkel Huinink\}, W.W. and A. Bult and J.H. Beijnen",

year = "1999",

language = "Undefined/Unknown",

volume = "24",

pages = "69--77",

journal = "European Journal of Drug Metabolism and Pharmacokinetics",

issn = "0378-7966",

publisher = "Adis",

}

Rosing, H, ten Bokkel Huinink, WW, Bult, A & Beijnen, JH 1999, 'Comparitive open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane 7 and ICRF-187) in patients with advanced breast cancer; treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)', European Journal of Drug Metabolism and Pharmacokinetics, vol. 24, pp. 69-77.

Comparitive open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane 7 and ICRF-187) in patients with advanced breast cancer; treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). / Rosing, H.; ten Bokkel Huinink, W.W.; Bult, A. et al.
In: European Journal of Drug Metabolism and Pharmacokinetics, Vol. 24, 1999, p. 69-77.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Comparitive open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane 7 and ICRF-187) in patients with advanced breast cancer; treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)

AU - Rosing, H.

AU - ten Bokkel Huinink, W.W.

AU - Bult, A.

AU - Beijnen, J.H.

PY - 1999

Y1 - 1999

M3 - Article

SN - 0378-7966

VL - 24

SP - 69

EP - 77

JO - European Journal of Drug Metabolism and Pharmacokinetics

JF - European Journal of Drug Metabolism and Pharmacokinetics

ER -